儿童狼疮性肾炎临床特点及诊治现状

doi:10.12372/jcp.2023.23e0979

摘要/Abstract

摘要：

系统性红斑狼疮（SLE）是一种以免疫失调和自身抗体形成为特征的多系统自身免疫性疾病。随着治疗的进展，SLE患者的生存率显著提高。即便如此，狼疮性肾炎（LN）的发病率和死亡率仍较高。目前，关于儿童LN的诊治等相关数据仍然缺乏，其诊断、治疗和监测主要依据成人的相关指南。治疗以激素和免疫抑制剂为主；近期，生物制剂被用于治疗LN取得良好的效果，无明显的不良反应。本文就儿童LN的流行病学、临床特点、发病机制、诊断及治疗等进展进行阐述。

关键词: 狼疮性肾炎, 诊断, 治疗, 儿童

Abstract:

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by immune dysregulation and autoantibody formation. With the progress of treatment, the survival rate of SLE patients has improved significantly. Even so, lupus nephritis (LN) is associated with high morbidity and mortality. At present, there is a lack of data on LN in children, and its diagnosis, treatment and monitoring are mainly based on guidelines for adults. Treatment is mainly based on hormones and immunosuppressants. Recently, biologics have been used to treat LN with good results and no obvious adverse reactions. This article reviews the progress of epidemiology, clinical features, pathogenesis, diagnosis and treatment of LN in children.

Key words: lupus nephritis, diagnosis, treatment, child

夏正坤, 王忍. 儿童狼疮性肾炎临床特点及诊治现状[J]. 临床儿科杂志, 2023, 41(12): 881-886.

XIA Zhengkun, WANG Ren. Clinical characteristics and diagnosis of lupus nephritis in children[J]. Journal of Clinical Pediatrics, 2023, 41(12): 881-886.

参考文献 32

[1]	Chan EY, Yap DY, Wong WT, et al. Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis[J]. Kidney Int Rep, 2022, 8(1): 141-150.
[2]	Diaz-Frias J, Badri T. Neonatal lupus erythematosus[M]. Treasure Island (FL): StatPearls Publishing, 2023.
[3]	Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020[J]. Am J Kidney Dis, 2020, 76(2): 265-281. doi: S0272-6386(19)31170-9 pmid: 32220510
[4]	Qiu S, Zhang H, Yu S, et al. Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis[J]. Pediatr Nephrol, 2022, 37(2): 367-376. doi: 10.1007/s00467-021-05164-y
[5]	Shi Y, Bi D, Wang Y, et al. Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus[J]. Front Med (Lausanne), 2022, 9: 984183.
[6]	Gutiérrez-Suárez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1, 015 patients with juvenile-onset systemic lupus erythematosus[J]. Arthritis Rheum, 2006, 54(9): 2989-2996. doi: 10.1002/art.v54:9
[7]	Pinheiro SVB, Dias RF, Fabiano RCG, et al. Pediatric lupus nephritis[J]. J Bras Nefrol, 2019, 41(2): 252-265. doi: S0101-28002019000200252 pmid: 30465590
[8]	Weiss JE, Sison CP, Ilowite NT, et al. Flares in pediatric systemic lupus erythematosus[J]. J Rheumatol, 2007, 34(6): 1341-1344. pmid: 17477466
[9]	Aggarwal A, Phatak S, Srivastava P, et al. Outcomes in juvenile onset lupus: single center cohort from a developing country[J]. Lupus, 2018, 27(11): 1867-1875. doi: 10.1177/0961203318791046 pmid: 30071768
[10]	Yung S, Yap DY, Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies[J]. F1000 Res, 2020, 9: F1000 Faculty Rev-905.
[11]	Hagberg N, Rönnblom L. Interferon-α enhances the IL-12-induced STAT4 activation selectively in carriers of the STAT4 SLE risk allele rs7574865 [T][J]. Ann Rheum Dis, 2019, 78(3): 429-431. doi: 10.1136/annrheumdis-2018-213836 pmid: 30269051
[12]	Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal[J]. Ann Rheum Dis, 2019, 78(7): 947-956. doi: 10.1136/annrheumdis-2018-214856 pmid: 30782585
[13]	Peene I, Elewaut D. Changing the wolf from outside: how microbiota trigger systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(7): 867-869. doi: 10.1136/annrheumdis-2019-215221 pmid: 31076388
[14]	Kostopoulou M, Fanouriakis A, Bertsias G, et al. Annals of the rheumatic diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy[J]. Ann Rheum Dis, 2023, 82(6): 729-733. doi: 10.1136/ard-2023-223880
[15]	Frangou E, Chrysanthopoulou A, Mitsios A, et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)[J]. Ann Rheum Dis, 2019, 78(2): 238-248. doi: 10.1136/annrheumdis-2018-213181 pmid: 30563869
[16]	Reid S, Alexsson A, Frodlund M, et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus[J]. Ann Rheum Dis, 2020, 79(3): 363-369. doi: 10.1136/annrheumdis-2019-216227 pmid: 31826855
[17]	中华医学会儿科学分会免疫学组, 中华儿科杂志编辑委员会. 中国儿童系统性红斑狼疮诊断与治疗指南[J]. 中华儿科杂志, 2021, 59(12): 1009-1024.
[18]	Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. doi: 10.1136/annrheumdis-2020-216924 pmid: 32220834
[19]	中华医学会儿科学分会肾脏学组. 狼疮性肾炎诊治循证指南(2016)[J]. 中华儿科杂志, 2018, 56(2): 88-94.
[20]	Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kidney Int, 2004, 65(2): 521-530. doi: 10.1111/j.1523-1755.2004.00443.x pmid: 14717922
[21]	Kaneko M, Jackson SW. Recent advances in immuno-therapies for lupus nephritis[J]. Pediatr Nephrol, 2023, 38(4): 1001-1012. doi: 10.1007/s00467-022-05670-7
[22]	Štambuk SK, Padjen I, Jukić NB, et al. Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption[J]. Clin Rheumatol, 2023, 42(6): 1723-1725. doi: 10.1007/s10067-023-06611-x
[23]	Thakur N, Rai N, Batra P. Pediatric lupus nephritis-review of literature[J]. Curr Rheumatol Rev, 2017, 13(1): 29-36. doi: 10.2174/1573397112666160404124308 pmid: 27041086
[24]	Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial[J]. Ann Intern Med, 2015, 162(1): 18-26. doi: 10.7326/M14-1030 pmid: 25383558
[25]	Rovin BH, Solomons N, Pendergraft WF 3rd, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis[J]. Kidney Int, 2019, 95(1): 219-231. doi: S0085-2538(18)30628-8 pmid: 30420324
[26]	Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials[J]. Am J Kidney Dis, 2017, 70(3): 324-336. doi: 10.1053/j.ajkd.2016.12.008
[27]	van Gelder T, Lerma E, Engelke K, et al. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis[J]. Expert Rev Clin Pharmacol, 2022, 15(5): 515-529. doi: 10.1080/17512433.2022.2092470
[28]	中华医学会肾脏病学分会专家组. 利妥昔单抗在肾小球肾炎中应用的专家共识[J]. 中华肾脏病杂志, 2022, 38(2): 151-160. doi: 10.3760/cma.j.cn441217-20210615-00023
[29]	Yu C, Li P, Dang X, et al. Lupus nephritis: new progress in diagnosis and treatment[J]. J Autoimmun, 2022, 132: 102871. doi: 10.1016/j.jaut.2022.102871
[30]	Plüß M, Piantoni S, Tampe B, et al. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis[J]. Hum Vaccin Immunother, 2022, 18(5): 2072143. doi: 10.1080/21645515.2022.2072143
[31]	Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study[J]. Arthritis Rheumatol, 2014, 66(2): 379-389. doi: 10.1002/art.v66.2
[32]	ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study[J]. Arthritis Rheumatol, 2014, 66(11): 3096-3104. doi: 10.1002/art.v66.11